Similar articles

• Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate.

  Pien FD, Ho PW. Pien FD, et al. Am J Hosp Pharm. 1981 Jul;38(7):981-9. Am J Hosp Pharm. 1981. PMID: 7020413 Review.
• Amikacin: pharmacology, indications and cautions for use, and dose recommendations.

  Philips JB, Cassady G. Philips JB, et al. Semin Perinatol. 1982 Apr;6(2):166-71. Semin Perinatol. 1982. PMID: 7048537 Review. No abstract available.
• Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States.

  Lane AZ, Wright GE, Blair DC. Lane AZ, et al. Am J Med. 1977 Jun;62(6):911-8. doi: 10.1016/0002-9343(77)90660-x. Am J Med. 1977. PMID: 868905 No abstract available.
• Amikacin therapy for serious gram-negative bacillary infections.

  Meyer RD, Lewis RP, Carmalt ED, Finegold SM. Meyer RD, et al. Ann Intern Med. 1975 Dec;83(6):790-800. doi: 10.7326/0003-4819-83-6-790. Ann Intern Med. 1975. PMID: 1200524
• [Comparative studies on the problem of nephrotoxicity of the aminoglycosides: kanamycin, amikacin, butirosin and kanendomycin].

  Sack K, Züllich B, Eikenberg P. Sack K, et al. Verh Dtsch Ges Inn Med. 1976;82 Pt 2:1538-40. Verh Dtsch Ges Inn Med. 1976. PMID: 70900 German. No abstract available.